Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

KY61559X1045
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00XQZQTS9
MLTX
MoonLake Immunotherapeutics
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
MoonLake Immunotherapeutics
ISIN
KY61559X1045
TICKER
MLTX
MIC
XNAS
REUTERS
MLTX.OQ
BLOOMBERG
MLTX US
Mi., 24.06.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the pricing of an underwritten public offering of 9,000,000 Class A ordinary shares at a public offering price per share...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 22.06.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced a proposed public offering of $150 million of its Class A ordinary shares and, in lieu of Class A ordinary shares to cert...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
So., 21.06.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, June 21, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced the Week 52 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patients with...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
So., 10.05.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, May 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced a positive outcome of its final pre-BLA meeting held on April 1, 2026, with the FDA on the HS program of its Nanobody® S...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 28.03.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, March 28, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces long-term Week 40 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patient...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
So., 22.02.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, February 22, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces topline results from the S-OLARIS Phase 2 trial of SLK in patients with radiographic and non-radiographic axSpA and...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 02.02.2026       Moonlake Immunotherapeutics
KY61559X1045

ZUG, Switzerland, February 2, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces that the FDA has granted Fast Track designation for sonelokimab for the treatment of moderate‑to‑severe PPP. MoonLake...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 15.12.2025       Moonlake Immunotherapeutics
KY61559X1045

SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025....
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 15.12.2025       Moonlake Immunotherapeutics
KY61559X1045

The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MLTX du...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 15.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. (“MoonLake” or the “Company”) (NASDAQ: MLTX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. This...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 15.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).  Shareholders who purchased shares of MLTX during the class period listed are encour...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 15.12.2025       Moonlake Immunotherapeutics
KY61559X1045

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commiss...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
So., 14.12.2025       Moonlake Immunotherapeutics
KY61559X1045

San Francisco, California--(Newsfile Corp. - December 14, 2025) - Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025. The lawsuit alleges that MoonLake and certain executive...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
So., 14.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in MoonLake to Contact Him Directly to Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
So., 14.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 14, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 13.12.2025       Moonlake Immunotherapeutics
KY61559X1045

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired MoonLake Immunotherapeutics ("MoonLake" or the Company") (NASDAQ: MLTX) securities between March 10, 2024 and September 29, 2025, inc...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 12, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.12.2025       Moonlake Immunotherapeutics
KY61559X1045

SAN FRANCISCO, Dec. 12, 2025 /PRNewswire/ -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025....
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partn...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 12.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 12, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 11.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encoura...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 11.12.2025       Moonlake Immunotherapeutics
KY61559X1045

PHILADELPHIA, Dec. 11, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period")....
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 11.12.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Dec. 11, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  MoonLake Immunotherapeutics ("MoonLake " or "the Company") (NASDAQ: MLTX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 11.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 10, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline....
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 10.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025. The lawsuit alleges that MoonLake and certain executives made materially false and misleading statements regarding the...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 10.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 10, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 10.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.SO WHA...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 10.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 09.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Lead Partner Reed Kathrein Investigating Alleged Undisclosed Truth: Did SLK's Nanobody Structure Truly Confer a Superior Clinical Benefit Over Monoclonal Antibodies?SAN FRANCISCO, Dec. 9, 2025 /PRNewswire/ -- Global plaintiffs' rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 09.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 08.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.S...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 08.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in MoonLake to Contact Him Directly to Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 08.12.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Dec. 8, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MOONLAKE (MLTX) CLICK HERE BEFORE DECEM...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 08.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encourag...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 08.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 8, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are e...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 08.12.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Dec. 8, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder b...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
So., 07.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.S...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
So., 07.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 06.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.S...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 06.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 6, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are e...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 05.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 05.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.S...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 05.12.2025       Moonlake Immunotherapeutics
KY61559X1045

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partn...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 05.12.2025       Moonlake Immunotherapeutics
KY61559X1045

MLTX Investor with Losses Encourages to Contact Firm by Dec. 15 DeadlineSAN FRANCISCO, Dec. 5, 2025 /PRNewswire/ -- Global plaintiffs' rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX)...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 04.12.2025       Moonlake Immunotherapeutics
KY61559X1045

New York, New York--(Newsfile Corp. - December 4, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are e...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 04.12.2025       Moonlake Immunotherapeutics
KY61559X1045

NEW YORK, Dec. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encourag...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 04.12.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Dec. 4, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("MoonLake " or "the Company") (NASDAQ: MLTX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. S...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 04.12.2025       Moonlake Immunotherapeutics
KY61559X1045

LOS ANGELES, Dec. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder b...
Zur Nachricht
Moonlake Immunotherapeutics
Charts & Research Termsheets Terminal
Permalink